Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0AHKMF
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
US20240166759A1 Antibody1-L3
|
|||||
| Synonyms |
Antibody1-L3
Click to Show/Hide
|
|||||
| Organization |
ANGIEX, INC.
|
|||||
| Drug Status |
Investigative
|
|||||
| Drug-to-Antibody Ratio |
2
|
|||||
| Antibody Name |
undisclosed
|
|||||
| Antigen Name |
Transmembrane 4 L6 family member 1 (TM4SF1)
|
Antigen Info | ||||
| Payload Name |
Undisclosed
|
|||||
| Therapeutic Target |
Stimulator of interferon genes protein (STING1)
|
Target Info | ||||
| Linker Name |
Undisclosed
|
|||||
| Conjugate Type |
Random conjugation through reduced inter-chain cysteines.
|
|||||
General Information of The Activity Data Related to This ADC
Full List of Activity Data of This Antibody-drug Conjugate
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) | 0.14 nM | Positive TM4SF1 expression (TM4SF1+++/++) | ||
| Method Description |
Cells were treated incubated for 4 days with the antibody drug conjugate before assessing cell viability on day 5.
|
||||
| In Vitro Model | Sickle cell anemia, Sickle cell disease | MS1 cells | CVCL_YP26 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) | 6.5 nM | Positive TM4SF1 expression (TM4SF1+++/++) | ||
| Method Description |
Cells were treated incubated for 4 days with the antibody drug conjugate before assessing cell viability on day 5.
|
||||
| In Vitro Model | Mouse melanoma | B16F10 cells | CVCL_0159 | ||
References